Risk of nonsteroidal anti-inflammatory drug-associated renal dysfunction among neonates diagnosed with patent ductus arteriosus and treated with gentamicin

2017 ◽  
Vol 37 (10) ◽  
pp. 1093-1102 ◽  
Author(s):  
J E Constance ◽  
D Reith ◽  
R M Ward ◽  
A Balch ◽  
C Stockmann ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Renal Dysfunction ◽  
Ductus Arteriosus ◽  
Inflammatory Drug ◽  
Anti Inflammatory ◽  
Patent Ductus

Non-steroid anti-inflammatory drugs in the treatment of patent ductus arteriosus in European newborns

2009 ◽  
Vol 22 (sup3) ◽  
pp. 77-80 ◽  
Author(s):  
Hercília Guimarães ◽  
Gustavo Rocha ◽  
Teresa Tomé ◽  
Fani Anatolitou ◽  
Kosmas Sarafidis ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Patent Ductus

Renal safety of Non Steroidal Anti Inflammatory Drugs (NSAIDs) in the pharmacologic treatment of patent ductus arteriosus

2011 ◽  
Vol 24 (sup1) ◽  
pp. 50-52 ◽  
Author(s):  
Vassilios Fanos ◽  
Maria Antonietta Marcialis ◽  
Pier Paolo Bassareo ◽  
Roberto Antonucci ◽  
Marco Zaffanello ◽  
...  
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Pharmacologic Treatment ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Renal Safety ◽  
Patent Ductus

scholarly journals Repeated Bowel Perforations with Ibuprofen Lysine: A Case Report

2008 ◽  
Vol 13 (3) ◽  
pp. 166-169
Author(s):  
Gregory J. Peitz ◽  
Eric B. Hoie ◽  
Shannon Hoy ◽  
Ann Anderson-Berry
Keyword(s):  
Case Report ◽  
Adverse Effects ◽  
Patent Ductus Arteriosus ◽  
Premature Infant ◽  
Medical Management ◽  
Bowel Perforation ◽  
Ductus Arteriosus ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Patent Ductus

Non-steroidal anti-inflammatory drugs (NSAID) have been used to close the patent ductus arteriosus in neonates for over two decades. Ibuprofen lysine, a parenteral NSAID, is labeled for the treatment of patent ductus arteriosus in neonates who do not respond to conventional medical management. While sharing many of the same adverse effects as indomethacin, spontaneous bowel perforation has not been reported. We describe a premature infant that experienced isolated bowel perforations after treatment with ibuprofen lysine for symptomatic patent ductus arteriosus.

scholarly journals Acute kidney injury among preterm infants receiving non-steroidal anti-inflammatory drugs for patent ductus arteriosus

2020 ◽  
Author(s):  
Joseph Ting ◽  
Kate McDougal ◽  
Alanna De Mello ◽  
Eddie Kwan ◽  
Cherry Mammen
Keyword(s):  
Acute Kidney Injury ◽  
Treatment Group ◽  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Kidney Injury ◽  
Prophylaxis Group ◽  
Increased Risk ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Patent Ductus

Abstract Background: Nonsteroidal anti-inflammatory drugs (NSAID) are a frequently prescribed class of medication in the neonatal intensive care unit (NICU). Hospitalized patients receiving NSAID therapy are at an increased risk of acute kidney injury (AKI). Our primary objective was to reveal AKI epidemiology in NSAID-exposed premature infants admitted to the NICU using a standardized definition.Methods: This retrospective study included infants born at ≤34 weeks gestational age who received NSAID for intraventricular haemorrhage prophylaxis [“prophylaxis group”] or symptomatic treatment for patent ductus arteriosus (PDA) [“treatment group”] between January and December 2014 at British Columbia Women’s Hospital NICU. All available serum creatinine (SCr) and 12-hour urine output (UO) were recorded from admission till day 7 post NSAID exposure. AKI incidence was determined using the modified Kidney Disease: Improving Global Outcomes (KDIGO) classification with an increase in SCr (ΔSCr) (50% rise from prior SCr within 7 days or 26.5 mmol/L rise within 48 hours) and/or UO < 1 mL/kg/hour, excluding the first 24 h of life.Results: We identified 70 eligible subjects, 32 of whom received prophylactic NSAID (prophylaxis group), and 38 received indomethacin or ibuprofen for treatment of symptomatic PDA (treatment group), with an overall AKI incidence of 23% (16/70). The treatment group had a higher proportion of infants with SCr monitoring during the NSAID than the prophylaxis group (87% vs. 13%, p<0.001). Based upon the above defined criteria (fulfilling at least one—either the UO or SCr monitoring criteria), the prophylaxis group had a significantly lower AKI rate compared with the treatment group (9% vs. 34%; p=0.014). Conclusions: AKI incidence is higher in infants treated with NSAID for symptomatic PDA than in those treated prophylactically during the first day of life, based on the criteria applied. However, the burden of AKI may be underestimated in the prophylaxis group due to fewer available SCr values after exposure, and inability to utilize UO criteria in the 1st 24 hours of life. Standardized protocols for monitoring daily SCr and UO after exposure should be implemented for all neonates with NSAID exposure and should be considered to improve AKI recognition.

scholarly journals Nonsteroidal anti-inflammatory administration and patent ductus arteriosus ligation, a survey of practice preferences at US children’s hospitals

2016 ◽  
Vol 175 (6) ◽  
pp. 775-783 ◽  
Author(s):  
Jonathan L. Slaughter ◽  
Patricia B. Reagan ◽  
Roopali V. Bapat ◽  
Thomas B. Newman ◽  
Mark A. Klebanoff
Keyword(s):  
Patent Ductus Arteriosus ◽  
Ductus Arteriosus ◽  
Children's Hospitals ◽  
Children’S Hospitals ◽  
Anti Inflammatory ◽  
Patent Ductus
Sign in / Sign up

Export Citation Format

Share Document